[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hayat Abad Medical Complex, Peshawar\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":149},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,75,96,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100635613","phase-4-effect-of-preoperative-submucosal-dexamethasone-on-postoperative-discomfort-after-mandibular-third-molar-surgery-100635613",false,"NCT07554963","\"Effect of Preoperative Submucosal Dexamethasone on Postoperative Discomfort After Mandibular Third Molar Surgery\"","Effect of Preoperative 4 mg Submucosal Dexamethasone on Postoperative Discomfort After Impacted Mandibular Third Molar Surgery: A Randomized Controlled Trial","DEXA-M3M","Inclusion Criteria:\n\n* Adults aged 18 to 55 years\n* Patients requiring surgical extraction of impacted mandibular third molars\n* Patients willing to provide informed consent\n\nExclusion Criteria:\n\n* Patients with systemic diseases\n* Patients with periodontal disease\n* Pregnant or lactating women\n* Patients who have used antibiotics or anti-inflammatory drugs within the past 7 days\n* Patients with known hypersensitivity to dexamethasone","ALL","18 Years","55 Years",{"count":21,"type":22},268,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study aims to determine whether giving a single dose of dexamethasone before surgery can reduce pain and difficulty in opening the mouth after removal of an impacted lower wisdom tooth. Pain and limited mouth opening are common problems after this procedure and can affect eating, speaking, and daily activities.\n\nA total of 268 patients aged 18 to 55 years who require surgical removal of an impacted mandibular third molar will be included. Participants will be randomly assigned to one of two groups. One group will receive a 4 mg dexamethasone injection under the gum before surgery, while the other group will not receive this medication. All patients will undergo the same surgical procedure and receive standard postoperative care.\n\nPain will be measured using a visual analogue scale, and mouth opening will be assessed using a standard measuring method. These outcomes will be recorded on the second and seventh days after surgery.\n\nThe results of this study will help determine whether preoperative dexamethasone is an effective and simple method to reduce postoperative discomfort and improve recovery after third molar surgery.",[28,29,30],"Impacted Mandibular Third Molar","Postoperative Pain","Trismus",[32,33,34,29],"Dexamethasone","Third Molar Surgery","Impacted Tooth","NOT_YET_RECRUITING","2026-04-27",{"date":38,"type":39},"2026-05-01","ACTUAL",{"date":38,"type":22},{"date":42,"type":22},"2026-10-01",{"name":44,"class":45},"Hayat Abad Medical Complex, Peshawar","OTHER_GOV",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":74,"locationsCount":4},"100627792","phase-4-comparison-of-topical-calcipotriol-and-intralesional-steroids-in-alopecia-areata-100627792","NCT07453238","Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata","Comparison of Topical Calcipotriol Versus Intralesional Corticosteroids in the Treatment of Alopecia Areata: A Randomized Controlled Trial","CALISTA-AA","Inclusion Criteria:\n\n* Adults aged 18 to 50 years\n* Clinically diagnosed patchy alopecia areata\n* Scalp involvement of less than 50% (SALT score \\\u003C50%)\n* No topical or systemic treatment for alopecia areata within the previous 3 months\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Diffuse alopecia areata or scarring alopecia\n* Presence of other autoimmune diseases or significant systemic illness\n* Known hypersensitivity to calcipotriol or corticosteroids\n* Pregnant or lactating women\n* Current use of immunosuppressive therapy\n* Unwillingness to participate or provide informed consent","50 Years",{"count":56,"type":22},60,[25],"This randomized controlled trial compares the effectiveness of topical calcipotriol and intralesional corticosteroids in the treatment of alopecia areata. Alopecia areata is an autoimmune condition that causes non-scarring hair loss and can significantly affect quality of life. Intralesional corticosteroids are commonly used as first-line therapy; however, response rates vary and treatment may be associated with discomfort and local adverse effects.\n\nSixty adult patients with patchy alopecia areata involving less than 50% of the scalp were randomly assigned to receive either topical calcipotriol or intralesional corticosteroid injections for 12 weeks. Participants were evaluated at four-week intervals. Treatment response was assessed using the Severity of Alopecia Tool (SALT) score and percentage improvement from baseline.\n\nThe primary objective is to compare reduction in SALT score between the two treatment groups. Secondary outcomes include overall treatment efficacy and safety. The findings aim to determine whether topical calcipotriol provides superior or comparable clinical benefit to intralesional corticosteroids in patients with alopecia areata.",[60],"Alopecia Areata",[60,62,63,64,65,66,67],"Topical Calcipotriol","Intralesional Corticosteroids","Randomized Controlled Trial","Hair Regrowth","Vitamin D Analog","Patchy Alopecia","2026-03-02",{"date":70,"type":39},"2026-03-05",{"date":72,"type":22},"2026-04-01",{"date":42,"type":22},{"name":44,"class":45},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100626584","phase-4-comparative-evaluation-of-the-safety-and-effectiveness-of-crisaborole-ointment-2-versus-tacrolimus-ointment-01-for-the-topical-treatment-of-atopic-dermatitis-100626584","NCT07437534","Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis","Inclusion Criteria:\n\n\\* Patients aged ≥2 years of either gender.\n\nDiagnosed with mild to moderate atopic dermatitis based on Hanifin and Rajka criteria.\n\nSCORAD score between 15 and 40. Willing to participate and provide informed consent (from guardian for minors).\n\nExclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\* Severe atopic dermatitis (SCORAD \\> 40).\n\nHistory of hypersensitivity to tacrolimus or crisaborole. Use of systemic immunosuppressive therapy within the past 4 weeks. Presence of secondary bacterial or viral skin infection. Pregnant or lactating females.\n\n\\-","2 Years",{"count":83,"type":22},148,[25],"Atopic dermatitis (AD), commonly known as eczema, is a chronic skin condition that causes itchy, red, and scaly patches on the skin. It often starts in childhood but can continue into adulthood, affecting a person's quality of life. People with AD may also suffer from asthma or allergies, as these conditions are linked. The exact cause is unclear, but it involves a mix of genetics, immune system problems, and environmental factors\\*\\* like pollution or dry weather.\n\nIn developed countries, about 20% of children and 1-10% of adults have AD, and cases have been increasing over the years. In Asia, including Pakistan, studies suggest 3.5-20% of children and up to 10% of adults may have it. However, in Pakistan, only 10% of children and 2-5% of adults are officially diagnosed, likely because many cases go \\*untreated or misdiagnosed. People often try home remedies or self-medication before seeing a doctor, which delays proper care.\n\nCurrent Treatments and Their Problems\n\nThe standard treatment includes:\n\nMoisturizers - Help repair the skin barrier. Topical Steroids (creams\u002Fointments) - Reduce inflammation but can thin the skin if used too long.\n\nSteroid-Free Alternatives - Used to avoid steroid side effects.\n\nTwo key steroid-free options are:\n\nTacrolimus (0.1% ointment) - Works well for moderate-to-severe eczema but can cause burning, itching, and has a \\*\\*cancer risk warning (though rare).\n\nCrisaborole (2% ointment) - A newer treatment for mild-to-moderate eczema, with fewer side effects but less research on its long-term use.\n\nWhy This Study is Needed\n\nMost research on these treatments comes from Western countries, and Pakistani patients may respond differently due to:\n\nClimate\\* (hot, humid weather affects skin). Pollution and dust, which worsen eczema. Limited access to specialists, leading to late diagnosis. There are no direct comparisons\\* between tacrolimus and crisaborole in Pakistan, making it hard for doctors to choose the best option.\n\nWhat This Study Will Do\n\nThis research will \\*compare tacrolimus 0.1% and crisaborole 2% in Pakistani patients with eczema to see:\n\nWhich works better? (Measured by clear\u002Falmost clear skin after 6 weeks). Which is safer? (Fewer side effects like burning or infections). Which improves quality of life? (Less itching, better sleep). How the Study Will Work\n\nPatients (adults and children over 2 years) with mild-to-moderate eczema will be divided into two groups:\n\nOne group uses tacrolimus ointment twice daily. The other uses crisaborole ointment twice daily. Doctors will check their skin at start, 2 ,4 and 8 weeks\\* to see improvements. Side effects and patient feedback will be recorded. Expected Results Tacrolimus might work better for severe cases but could cause more irritation. Crisaborole may be gentler, especially for children and sensitive skin. The findings will help Pakistani doctors make better treatment choices and improve eczema care in the country.\n\nWhy This Matters Eczema is a lifelong condition, and using the wrong treatment can lead to worse flare-ups, infections, or side effects. Since steroids are overused in Pakistan, safer alternatives like tacrolimus and crisaborole need proper testing in local patients. This study will provide evidence-based guidelines for eczema treatment in Pakistan, helping patients get effective and safe care",[87],"Atopic Dermatitis","2026-02-26",{"date":68,"type":39},{"date":91,"type":22},"2026-03-01",{"date":93,"type":22},"2026-08-30",{"name":44,"class":45},1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100624174","phase-4-tofacitinib-vs-methotrexate-for-severe-alopecia-areata-tofa-mtx-aa-100624174","NCT07406204","Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)","Comparative Clinical Efficacy of Tofacitinib Versus Methotrexate in Severe Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Randomized Controlled Trial","TOFA-MTX-AA","Inclusion Criteria:\n\nAdults aged 18-60 years.\n\nClinical diagnosis of severe alopecia areata, alopecia totalis, or alopecia universalis (as per protocol\u002Foperational definition), confirmed by a consultant dermatologist.\n\nEither sex.\n\nAble and willing to provide written informed consent.\n\nExclusion Criteria:\n\nCurrently receiving or recently used any systemic treatment intended for hair regrowth for alopecia areata (e.g., systemic corticosteroids, immunosuppressants, JAK inhibitors).\n\nPregnant women.\n\nHistory or clinical evidence of renal, hepatic, or pulmonary disease.\n\nAny condition that, in the investigator's judgment, makes participation unsafe or interferes with adherence to the study protocol.","60 Years",{"count":106,"type":22},78,[25],"This study will compare two oral medicines-tofacitinib and methotrexate-for treating severe alopecia areata, including alopecia totalis (loss of all scalp hair) and alopecia universalis (loss of scalp and body hair). Alopecia areata is an autoimmune condition that can cause significant hair loss and emotional distress.\n\nAdults aged 18 to 60 years with severe disease will be enrolled at the Department of Dermatology, MTI-Hayatabad Medical Complex, Peshawar, after ethical approval and written informed consent. Participants will be randomly assigned to receive either tofacitinib 10 mg twice daily or methotrexate 0.2-0.4 mg\u002Fkg once weekly for 12 weeks.\n\nThe main outcome will be improvement in hair loss measured by the Severity of Alopecia Tool (SALT) score. Treatment will be considered effective if there is more than 50% improvement in SALT score from baseline at the end of 12 weeks. Safety will be monitored during follow-up visits. The findings may help guide treatment decisions for severe alopecia areata in our local population.",[60,110,111],"Alopecia Totalis (AT)","Alopecia Universalis",[113,114,115,116,117],"Tofacitinib","Methotrexate","Janus Kinase Inhibitor","Severe Alopecia Areata","Autoimmune Hair Loss","2026-02-05",{"date":120,"type":39},"2026-02-12",{"date":122,"type":22},"2026-02-15",{"date":124,"type":22},"2026-08-15",{"name":44,"class":45},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":133,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":95},"100597210","early-phase-1-comparison-of-efficacy-and-safety-psoralen-combined-with-ultraviolet-a-puva-vs-tofacitinib-in-the-treatment-of-generalized-vitiligo-100597210","NCT07055529","Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.","(PUVA)","Inclusion Criteria:\n\n* • Patients of either gender aged 18-60 years, diagnosed with generalized vitiligo (depigmentation affecting more than 10% of the body surface area).\n\n  * Stable vitiligo (no new lesions or progression of existing lesions in the last three months).\n\nExclusion Criteria:\n\n* Patients with a history of photosensitivity or allergies to Psoralen or Tofacitinib in order to prevent adverse reactions that could compromise patient safety and interfere with treatment efficacy assessment.\n* Pregnant or lactating women in order to ensure fetal and neonatal safety, as the effects of Psoralen and Tofacitinib on pregnancy and breastfeeding are not well studied and could pose potential risks.",true,{"count":135,"type":22},64,[137],"EARLY_PHASE1","This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies.",[140],"Vitiligo, Generalized","2026-01-29",{"date":143,"type":39},"2026-01-30",{"date":145,"type":22},"2026-06-01",{"date":147,"type":22},"2026-12-31",{"name":44,"class":45},""]